Literature DB >> 32782380

TrkB receptor cleavage by delta-secretase abolishes its phosphorylation of APP, aggravating Alzheimer's disease pathologies.

Yiyuan Xia1,2, Zhi-Hao Wang1, Pai Liu1,3, Laura Edgington-Mitchell4, Xia Liu1, Xiao-Chuan Wang5,6, Keqiang Ye7.   

Abstract

Neurotrophins promote neuronal survival and synaptic plasticity via activating the tropomyosin receptor kinases. BDNF and its high-affinity receptor TrkB are reduced in Alzheimer's disease (AD), contributing to progressive cognitive decline. However, how the signaling mediates AD pathologies remains incompletely understood. Here we show that the TrkB receptor binds and phosphorylates APP, reducing amyloid-β production, which are abrogated by δ-secretase cleavage of TrkB in AD. Remarkably, BDNF stimulates TrkB to phosphorylate APP Y687 residue that accumulates APP in the TGN (Trans-Golgi Network) and diminishes its amyloidogenic cleavage. Delta-secretase cleaves TrkB at N365 and N486/489 residues and abolishes its neurotrophic activity, decreasing p-APP Y687 and altering its subcellular trafficking. Notably, both TrkB and APP are robustly cleaved by δ-secretase in AD brains, accompanied by mitigated TrkB signaling and reduced p-Y687. Blockade of TrkB cleavage attenuates AD pathologies in 5xFAD mice, rescuing the learning and memory. Viral expression of TrkB 1-486 fragment in the hippocampus of APP/PS1 mice facilitates amyloid pathology and mitigates cognitive functions. Hence, δ-secretase cleaves TrkB and blunts its phosphorylation of APP, facilitating AD pathogenesis.
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32782380     DOI: 10.1038/s41380-020-00863-8

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  48 in total

1.  Trophic factor effects on septal cholinergic neurons.

Authors:  C N Svendsen; J D Cooper; M V Sofroniew
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

Review 2.  Neurotrophin-regulated signalling pathways.

Authors:  Louis F Reichardt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-09-29       Impact factor: 6.237

3.  NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease.

Authors:  R Hellweg; C A Gericke; K Jendroska; H D Hartung; J Cervós-Navarro
Journal:  Int J Dev Neurosci       Date:  1998 Nov-Dec       Impact factor: 2.457

4.  Brain-derived neurotrophic factor is reduced in Alzheimer's disease.

Authors:  B Connor; D Young; Q Yan; R L Faull; B Synek; M Dragunow
Journal:  Brain Res Mol Brain Res       Date:  1997-10-03

5.  BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies.

Authors:  I Ferrer; C Marín; M J Rey; T Ribalta; E Goutan; R Blanco; E Tolosa; E Martí
Journal:  J Neuropathol Exp Neurol       Date:  1999-07       Impact factor: 3.685

Review 6.  The role of neurotrophins and insulin on tau pathology in Alzheimer's disease.

Authors:  Evan Elliott; Irith Ginzburg
Journal:  Rev Neurosci       Date:  2006       Impact factor: 4.353

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease.

Authors:  Shiyong Peng; Joanne Wuu; Elliott J Mufson; Margaret Fahnestock
Journal:  J Neuropathol Exp Neurol       Date:  2004-06       Impact factor: 3.685

9.  BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease.

Authors:  H S Phillips; J M Hains; M Armanini; G R Laramee; S A Johnson; J W Winslow
Journal:  Neuron       Date:  1991-11       Impact factor: 17.173

10.  Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease.

Authors:  K A Crutcher; S A Scott; S Liang; W V Everson; J Weingartner
Journal:  J Neurosci       Date:  1993-06       Impact factor: 6.167

View more
  6 in total

Review 1.  Psychedelic-inspired approaches for treating neurodegenerative disorders.

Authors:  Hannah N Saeger; David E Olson
Journal:  J Neurochem       Date:  2021-12-05       Impact factor: 5.546

Review 2.  Proteolytic Cleavage of Receptor Tyrosine Kinases.

Authors:  Hao Huang
Journal:  Biomolecules       Date:  2021-04-29

3.  Asparagine Endopeptidase (δ Secretase), an Enzyme Implicated in Alzheimer's Disease Pathology, Is an Inhibitor of Axon Regeneration in Peripheral Nerves.

Authors:  Arthur W English; Xia Liu; Olivia C Mistretta; Patricia J Ward; Keqiang Ye
Journal:  eNeuro       Date:  2021-01-15

Review 4.  Genetic Variants behind Cardiovascular Diseases and Dementia.

Authors:  Wei-Min Ho; Yah-Yuan Wu; Yi-Chun Chen
Journal:  Genes (Basel)       Date:  2020-12-18       Impact factor: 4.096

5.  Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD.

Authors:  Shanshan Wang; Joseph S Leem; Sonia Podvin; Vivian Hook; Natalia Kleschevnikov; Paul Savchenko; Mehul Dhanani; Kimberly Zhou; Isabella C Kelly; Tong Zhang; Atsushi Miyanohara; Phuong Nguyen; Alexander Kleschevnikov; Steve L Wagner; John Q Trojanowski; David M Roth; Hemal H Patel; Piyush M Patel; Brian P Head
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-29       Impact factor: 6.698

Review 6.  Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential.

Authors:  Lina Gao; Yun Zhang; Keenan Sterling; Weihong Song
Journal:  Transl Neurodegener       Date:  2022-01-28       Impact factor: 8.014

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.